MKC.V

The article recommends a buy-and-hold strategy for patient investors, suggesting $1,000 allocations across five dividend-paying consumer stocks with specific growth projects expected to mature by 2031. Each company is executing strategic initiatives—from brand expansion to acquisitions—that should drive long-term value creation.

Consumer staples companies PepsiCo, McCormick, Hormel, and Clorox are trading near 52-week lows due to headwinds including changing consumer preferences toward healthier products, budget constraints, and rising costs. However, these companies offer attractive dividend yields (4.1%-5.7%) and have proven track records as dividend growers, making them potentially opportunistic buys for long-term dividend investors.

The article outlines a foundational approach to investing, emphasizing the importance of saving money before investing and building an emergency fund. It recommends a long-term strategy of buying well-run companies at attractive valuations, inspired by Warren Buffett's philosophy. The author specifically recommends PepsiCo and McCormick as suitable starting stocks for new investors due to their stability, longevity, dividend yields, and consumer staples business models.

The author recommends five dividend stocks currently out of favor: PepsiCo, Hormel, Hershey, McCormick, and Realty Income. Despite near-term headwinds from inflation and rising interest rates, the author believes these companies have strong fundamentals, long histories of dividend increases, and will navigate current challenges successfully. He advocates a long-term buy-and-hold approach with dividend reinvestment, ignoring short-term stock price fluctuations.

The author argues that most investors misunderstand the stock market by focusing on short-term price movements rather than long-term business value. He explains Benjamin Graham's concept of the stock market as a 'voting machine' in the short term (driven by emotions) and a 'weighing machine' in the long term (reflecting true value). Taking advantage of current market pessimism, the author has doubled his position in McCormick, a well-run consumer staples company with a 4% dividend yield, believing Wall Street is undervaluing it despite solid fundamentals and a planned acquisition of Unilever's food business.

The author recommends two high-yield dividend stocks for October: Medtronic (MDT), which has completed a business overhaul and is approaching Dividend King status with a 3.3% yield, and McCormick (MKC), a consumer staples company with 39 years of dividend increases and a 4.2% yield that is acquiring Unilever's food business to roughly double its sales.

Lawrence Erik Kurzius, a Director at Cooper Companies, purchased 10,000 shares worth $549,300 at $54.93 per share on September 16, 2026, increasing his total holdings to 31,099 shares. The insider buy signals confidence in the company's recovery prospects following a 16% stock decline over the past year. The article notes that insider purchases typically predict higher share prices within 30 days and suggest management believes in the company's long-term growth, particularly after deciding to retain its surgical unit rather than divest it.

McCormick & Company delivered solid Q3 fiscal 2026 results with net sales rising 17.4% to $2,024.8 million, driven by the McCormick de Mexico acquisition and 1.9% organic growth. Adjusted earnings of 86 cents per share beat consensus estimates, while adjusted gross margin expanded 180 basis points to 39.3%. The company reaffirmed its fiscal 2026 outlook but expects higher commodity and freight costs in Q4, with a packaging constraint potentially reducing full-year organic growth by 30 basis points.

McCormick reported Q3 earnings of $0.86 per share, beating consensus estimates of $0.75, with revenues of $2.02 billion exceeding expectations. However, the stock carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions and has underperformed the market by 31.9% year-to-date. Mondelez is expected to report Q3 earnings of $0.71 per share with revenues of $9.97 billion.

McCormick & Company is expected to report Q3 2026 revenues rising 14.7% to ~$2 billion, but earnings may fall 11.8% to 75 cents per share. Growth drivers include the Flavor Solutions segment, pricing actions, and CCI productivity savings, while headwinds include consumer price sensitivity, competitive pressures, and inflationary expenses. The company carries a Zacks Rank #4 (Sell) with a negative Earnings ESP of -1.97%, suggesting limited likelihood of an earnings beat.